Polypeptide and application thereof
By binding to XOD, the polypeptide isolated from the giant salamander bone peptide extract, inhibiting its activity, solving the problem of elevated uric acid levels, and achieving effective hyperuricemia treatment and renal protection.
Patent Information
- Application Number
- CN202310523668.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-05-10
AI Technical Summary
The prior art is difficult to effectively inhibit xanthine oxidase (XOD) activity, resulting in an increase in uric acid levels and is unable to effectively treat hyperuricemia.
A polypeptide is developed to inhibit its activity by binding to XOD and combining it with a carrier or excipient to form a composition that can be used in a pharmaceutical manner for lowering uric acid levels. The polypeptide was isolated from the giant salamander bone peptide extract and was isolated by enzymatic lysis, alcohol precipitation and high performance liquid chromatography, with a significant XOD inhibition rate.
It significantly inhibits XOD activity in vitro and in vivo, reduces uric acid levels, effectively treats hyperuricemia, and has potential renal protection effects.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of polypeptide preparation, and in particular to a polypeptide and its application. Background Art
[0002] The Chinese giant salamander (Latin name: Andrias davidianus) is the largest existing amphibian in the world, with extremely high edible and medicinal value, and great development and application potential in the field of life and health. Wild giant salamanders are a second-class protected aquatic animal in China, but in the past two decades, the artificial breeding technology of giant salamanders has gradually matured, and the giant salamander industry has developed rapidly. In Shaanxi, Hunan, Henan, Sichuan and other provinces and regions, a large-scale breeding giant salamander industry and market has been formed, which provides a sustainable biological resource for the extraction of life and health products with medical and health value from giant salamander bones. Summary of the invention
[0003] The present application provides a polypeptide, which can inhibit the activity of XOD in vitro, and can inhibit the activity of XOD in vivo to reduce uric acid, and can improve hyperuricemia.
[0004] The specific technical solutions of this application are as follows:
[0005] 1. A polypeptide, wherein the polypeptide is selected from any one of SEQ ID Nos: 1-42.
[0006] 2. A nucleic acid encoding the polypeptide described in item 1.
[0007] 3. A composition comprising the polypeptide described in item 1.
[0008] 4. The composition according to item 3, further comprising pharmaceutically, food or health product acceptable carriers, excipients and active ingredients.
[0009] 5. Use of the polypeptide described in item 1 or the composition described in item 3 or 4 in the preparation of a drug for lowering uric acid or treating hyperuricemia.
[0010] 6. A drug for lowering uric acid or treating hyperuricemia, comprising the polypeptide described in item 1 or the composition described in item 3 or 4.
[0011] Effects of the Invention
[0012] The polypeptide described in the present application can bind to the XOD enzyme, thereby inhibiting the activity of the XOD enzyme and reducing uric acid. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is a schematic diagram of the molecular weight distribution of giant salamander bone peptide extract (ADBP).
[0014] Figure 2 It is a schematic diagram of the primary separation and secondary separation of giant salamander bone peptide extract (ADBP) and a schematic diagram of the XOD inhibition rate, wherein: Figure 2 A in the figure is a schematic diagram of the initial separation of ADBP. Figure 2 B in the figure is a schematic diagram of the inhibition rate of XOD by the product of the initial separation of ADBP. Figure 2 C in the figure is a schematic diagram of secondary separation of the product with higher XOD inhibition rate in the primary separation. Figure 2 D in the figure is a schematic diagram of the XOD inhibition rate of the secondary separation product.
[0015] Figure 3 This is a schematic diagram of the uric acid-lowering effect of peptides on hyperuricemia mice, where: Figure 3 A in the figure is a schematic diagram of experimental data. Figure 3 B in the figure is a schematic diagram of xanthine oxidase activity in the liver. Figure 3 The C in the figure is a diagram of blood uric acid level. Figure 3 D in the figure is a diagram of blood creatinine level. Figure 3 E in the figure is a schematic diagram of blood urea nitrogen level. DETAILED DESCRIPTION
[0016] The present application is described in detail below in conjunction with the embodiments described in the accompanying drawings, wherein the same numbers in all the accompanying drawings represent the same features. Although specific embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present application and to be able to fully convey the scope of the present application to those skilled in the art.
[0017] It should be noted that certain words are used in the specification and claims to refer to specific components. Those skilled in the art should understand that technicians may use different nouns to refer to the same component. This specification and claims do not use the difference in nouns as a way to distinguish components, but use the functional differences of components as the criterion for distinction. As mentioned throughout the specification and claims, "including" or "comprising" are open-ended terms and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment of the present application, but the description is based on the general principles of the specification and is not intended to limit the scope of the present application. The scope of protection of the present application shall be determined by the attached claims.
[0018] The present application provides a polypeptide, wherein the polypeptide is selected from any one of SEQ ID Nos: 1-42.
[0019] Wherein, the sequence of SEQ ID NO:1 is TEAPLNPK;
[0020] The sequence of SEQ ID NO:2 is HDEPVTIPNKPN; the sequence of SEQ ID NO:3 is GPRGPQGPS; the sequence of SEQ ID NO:4 is RGPPGPS;
[0021] The sequence of SEQ ID NO:5 is LDFE;
[0022] The sequence of SEQ ID NO:6 is PAW;
[0023] The sequence of SEQ ID NO:7 is GPAGPSGPR; the sequence of SEQ ID NO:8 is AVLVFR;
[0024] The sequence of SEQ ID NO:9 is VLIPVK;
[0025] The sequence of SEQ ID NO: 10 is VMVLEIR; the sequence of SEQ ID NO: 11 is ALSLPLIK; the sequence of SEQ ID NO: 12 is IIPNIVK;
[0026] The sequence of SEQ ID NO: 13 is ALTLDIY; the sequence of SEQ ID NO: 14 is IIWEFIK;
[0027] The sequence of SEQ ID NO: 15 is DVLNLVY; the sequence of SEQ ID NO: 16 is YLAFLR; the sequence of SEQ ID NO: 17 is FFAAFASR; the sequence of SEQ ID NO: 18 is YALVFFYR; the sequence of SEQ ID NO: 19 is LNLNVLY; the sequence of SEQ ID NO: 20 is DLMLW;
[0028] The sequence of SEQ ID NO:21 is VGW;
[0029] The sequence of SEQ ID NO:22 is NENIIIL;
[0030] The sequence of SEQ ID NO:23 is VTIETVY; the sequence of SEQ ID NO:24 is EVLMLR; the sequence of SEQ ID NO:25 is VNWL;
[0031] The sequence of SEQ ID NO:26 is LMISMLDR; the sequence of SEQ ID NO:27 is FLDCAFR; the sequence of SEQ ID NO:28 is MWLP;
[0032] The sequence of SEQ ID NO:29 is FWFP;
[0033] The sequence of SEQ ID NO:30 is TWL;
[0034] The sequence of SEQ ID NO:31 is AHF;
[0035] The sequence of SEQ ID NO:32 is FTLR;
[0036] The sequence of SEQ ID NO:33 is DMLLR;
[0037] The sequence of SEQ ID NO:34 is SHIADF;
[0038] The sequence of SEQ ID NO:35 is IPYW;
[0039] The sequence of SEQ ID NO:36 is WPF;
[0040] The sequence of SEQ ID NO:37 is FWYY;
[0041] The sequence of SEQ ID NO:38 is DWF;
[0042] The sequence of SEQ ID NO:39 is FWQ;
[0043] The sequence of SEQ ID NO:40 is PHF;
[0044] The sequence of SEQ ID NO:41 is FDEW;
[0045] The sequence of SEQ ID NO:42 is FWER.
[0046] Among them, SEQ ID Nos: 1-7 are obtained by a "top-down" method, which is to enzymatically hydrolyze giant salamander bone powder and then ethanol precipitate to obtain giant salamander bone peptide extract (ADBP), and then separate the giant salamander bone peptide extract and determine the XOD inhibition rate to obtain the polypeptides described in SEQ ID Nos: 1-7.
[0047] In some embodiments, the preparation method of giant salamander bone peptide extract (ADBP) is as follows:
[0048] The giant salamander bone powder is subjected to protease enzymolysis and centrifugation to obtain a supernatant as the giant salamander bone powder enzymolysis extract;
[0049] The giant salamander bone powder enzymatic hydrolysis extract was subjected to alcohol precipitation and centrifugation to obtain the giant salamander bone peptide extract (ADBP).
[0050] In some embodiments, the protease is alkaline protease, preferably 2709 alkaline protease; preferably, the protease hydrolysis is carried out at 30-40°C; preferably, the protease hydrolysis is carried out at a pH of 9-11; preferably, the hydrolysis time is 3-6h; preferably, the mass ratio of protease to giant salamander bone powder is 1:6-15. In some embodiments, ethanol is used for alcohol precipitation, preferably, the mass concentration of the ethanol is 55-85%; preferably, the alcohol precipitation time is 3-12h.
[0051] In some embodiments, the obtained giant salamander bone peptide extract is separated by a conventional high performance liquid separation method, and the xanthine oxidase (XOD) inhibition rate of each separated product is evaluated by a chemical method, and the product with a higher XOD inhibition rate is selected for secondary separation to obtain a secondary separated product, and the XOD inhibition rate of each secondary separated product is evaluated, and the secondary separated product with a higher XOD inhibition rate is identified by mass spectrometry to obtain the polypeptides described in SEQ ID NOs: 1-7.
[0052] In some embodiments, the chromatographic conditions for the second separation are the same as the chromatographic conditions for the above separation.
[0053] In some embodiments, the conditions of the high performance liquid chromatography are:
[0054] The chromatographic column is an Agilent 5prep-C18 column; and / or
[0055] Mobile phase A: an aqueous solution containing 0.05-0.1 wt% TFA; mobile phase B is an acetonitrile solution containing 0.05-0.1 wt% TFA, preferably, the volume ratio of mobile phase A to mobile phase B is 5-25:95-75; and / or
[0056] Flow rate of 5-15 mL / min; and / or
[0057] The injection volume is 0.5-1.5mL; and / or
[0058] The detection wavelength is 210-220nm or 280nm.
[0059] In the present application, there is no limitation on the determination of the content of protein in the giant salamander bone peptide extract, which can be determined according to conventional methods in the art, for example, by the method for determining protein in the first method of national standard GB 5009.5-2016.
[0060] In some embodiments, based on the giant salamander bone peptide extract, glycine is 4-11 mg / kg; and / or alanine is 2-9 mg / kg; and / or valine is 0.5-7 mg / kg; and / or leucine is 2-9 mg / kg; and / or isoleucine is 2-7 mg / kg; and / or proline is 2-9 mg / kg; and / or phenylalanine is 1-7 mg / kg; and / or methionine is 0-4 mg / kg; and / or tyrosine is 0-6 mg / kg; and / or serine is 1-8 mg / kg; and / or threonine is 0-7 mg / kg; and / or aspartic acid is 3-10 mg / kg; and / or glutamic acid is 9-15 mg / kg; and / or lysine is 2-9 mg / kg; and / or arginine is 2-9 mg / kg; and / or histidine is 0-5 mg / kg.
[0061] For example, based on the giant salamander bone peptide extract, glycine can be 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, etc.;
[0062] Alanine can be 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, etc.;
[0063] Valine can be 0.5mg / kg, 1mg / kg, 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, etc.;
[0064] Leucine can be 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, etc.;
[0065] Isoleucine can be 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, etc.;
[0066] Proline can be 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, etc.;
[0067] Phenylalanine can be 1mg / kg, 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, etc.;
[0068] Methionine can be 0, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, etc.;
[0069] Tyrosine can be 0, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, etc.;
[0070] Serine can be 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, etc.;
[0071] Threonine can be 0, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, etc.;
[0072] Aspartic acid can be 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, 10mg / kg, etc.;
[0073] Glutamic acid can be 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, etc.;
[0074] Lysine can be 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, etc.;
[0075] Arginine can be 2mg / kg, 3mg / kg, 4mg / kg, 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, etc.;
[0076] Histidine can be 0, 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, etc.
[0077] In the present application, there is no limitation on the method for determining the amino acid content in the giant salamander bone peptide extract, which can be determined according to conventional methods in the art, for example, the method in national standard GB 5009.124-2016 can be used for determination.
[0078] In the present application, the method for determining the amino acid sequence of the polypeptide is not limited in any way. The method can be determined according to conventional methods in the art, for example, UPLC-Orbitrap Fusion MS method can be used for determination. For example, an aqueous solution containing 0.1% TFA can be used as mobile phase A, and an acetonitrile solution containing 0.15 TFA can be used as mobile phase B for gradient elution. Preferably, the method of gradient elution is as follows:
[0079] 0-2 min, 3-7 vol% mobile phase B;
[0080] 2-52 min, 7-22 vol% mobile phase B;
[0081] 52-62 min, 22-35 vol% mobile phase B;
[0082] 62-64 min, 35-90 vol% mobile phase B;
[0083] 64-84 min, 90 vol% mobile phase B
[0084] In some embodiments, the flow rate is 250 nL / min. In some embodiments, the mass spectrometry conditions are: m / z scanning range 300-2000, resolution 120000, target ions 2×10 5 In the present application, there is no limitation on the method for determining the abundance, which can be determined according to conventional methods in the art, for example, it can be calculated using Proteindiscorvery software.
[0085] In some embodiments, the weight average molecular weight of the giant salamander bone peptide extract is 490-600 g / mol, preferably 490-550 g / mol, and further preferably 490-530 g / mol;
[0086] Preferably, the number average molecular weight of the giant salamander bone peptide extract is 300-600 g / mol, preferably 350-550 g / mol.
[0087] For example, the weight average molecular weight of the giant salamander bone peptide extract can be 490g / mol, 500g / mol, 510g / mol, 520g / mol, 530g / mol, 540g / mol, 550g / mol, 560g / mol, 570g / mol, 580g / mol, 590g / mol, 600g / mol, etc.; the number average molecular weight of the giant salamander bone peptide extract can be 300g / mol, 310g / mol, 320g / mol, 330g / mol, 340g / mol, 350g / mol, 360g / mol, 370 g / mol, 380g / mol, 390g / mol, 400g / mol, 410g / mol, 420g / mol, 430g / mol, 440g / mol, 450g / mol, 460g / mol, 470g / mol, 480g / mol, 49 0g / mol, 500g / mol, 510g / mol, 520g / mol, 530g / mol, 540g / mol, 550g / mol, 560g / mol, 570g / mol, 580g / mol, 590g / mol, 600g / mol, etc.
[0088] In some embodiments, the weight average molecular weight of the giant salamander bone peptide extract is 513±17.04 g / mol, and the number average molecular weight is 454.67±97.35 g / mol.
[0089] In the present application, there is no limitation on the method for determining the weight average molecular weight of the giant salamander bone peptide extract, which can be determined according to conventional methods in the art, for example, by GPC analysis.
[0090] In some embodiments, the phosphorus content in the giant salamander bone peptide extract is 600.00-900.00 mg / kg, preferably 628.43-888.90 mg / kg; potassium is 7000.00-9000.00 mg / kg, preferably 7177.97-8308.69 mg / kg; sodium is 5000.00-6000.00 mg / kg, preferably 5571.64-5901.69 mg / kg; iron is 6.00-7.00 mg / kg, preferably 6.36-6.67 mg / kg, zinc is 3.00-4.00 mg / kg, preferably 3.37-3.63 mg / kg and selenium is 0.50-1.00 mg / kg, preferably 0.64-0.73 mg / kg.
[0091] For example, the phosphorus content in the giant salamander bone peptide extract may be 600.00 mg / kg, 650.00 mg / kg, 700.00 mg / kg, 750.00 mg / kg, 800.00 mg / kg, 850.00 mg / kg, 900.00 mg / kg, etc.;
[0092] Potassium can be 7000.00mg / kg, 7100.00mg / kg, 7200.00mg / kg, 7300.00mg / kg, 7400.00mg / kg, 7500.00mg / kg, 7600.00mg / kg, 7700.00mg / kg, 7800.00mg / kg, 7900.00mg / kg, 8000.00mg / kg, 8100.00mg / kg, 8200.00mg / kg, 8300.00mg / kg, 8400.00mg / kg, 8500.00mg / kg, 8600.00mg / kg, 8700.00mg / kg, 8800.00mg / kg, 8900.00mg / kg, 9000.00mg / kg, etc.;
[0093] Sodium can be 5000.00 mg / kg, 5100.00 mg / kg, 5200.00 mg / kg, 5300.00 mg / kg, 5400.00 mg / kg, 5500.00 mg / kg, 5500.00 mg / kg, 5600.00 mg / kg, 5700.00 mg / kg, 5800.00 mg / kg, 5900.00 mg / kg, 6000.00 mg / kg, etc.;
[0094] Iron can be 6.00 mg / kg, 6.10 mg / kg, 6.20 mg / kg, 6.30 mg / kg, 6.40 mg / kg, 6.50 mg / kg, 6.60 mg / kg, 6.60 mg / kg, 6.70 mg / kg, 6.80 mg / kg, 6.90 mg / kg, 7.00 mg / kg, etc.;
[0095] Zinc can be 3.00 mg / kg, 3.10 mg / kg, 3.20 mg / kg, 3.30 mg / kg, 3.40 mg / kg, 3.50 mg / kg, 3.60 mg / kg, 3.70 mg / kg, 3.80 mg / kg, 3.90 mg / kg, 4.00 mg / kg, etc.;
[0096] Selenium can be 0.50 mg / kg, 0.64 mg / kg, 0.65 mg / kg, 0.66 mg / kg, 0.67 mg / kg, 0.68 mg / kg, 0.69 mg / kg, 0.70 mg / kg, 0.71 mg / kg, 0.72 mg / kg, 0.73 mg / kg, 0.80 mg / kg, 0.90 mg / kg, 1.00 mg / kg, etc.
[0097] In the present application, there is no limitation on the method for determining the content of major elements and trace elements in giant salamander bone peptide extract, which can be determined according to conventional methods in the art, for example, the method in the first method of national standard GB5009.268-2016 can be used for determination.
[0098] In some embodiments, SEQ ID Nos: 8-42 are obtained by a "bottom-up" method, which is to obtain the transcriptome information of giant salamander cartilage by conventional transcriptomics methods, obtain proteins by simulated translation, and thus establish a giant salamander cartilage protein library, which is used as a protein sequence information comparison database required for protein identification, and the giant salamander cartilage is subjected to proteomics sequencing to obtain polypeptide sequences, and the comparative database is used as a reference to obtain proteins, and the proteins are subjected to single enzyme and compound enzyme simulated enzyme digestion to establish a giant salamander cartilage polypeptide library. With reference to known polypeptide sequences reported in the literature, the above giant salamander polypeptide library is screened by machine learning, and the obtained polypeptides are molecularly docked with XOD to obtain polypeptides that bind well to XOD, and are sorted according to hydrophobicity, thereby obtaining polypeptides of SEQ ID NOs: 8-42.
[0099] The polypeptide described in the present application has a good inhibition rate on XOD, and its IC50 is 0.31-0.35 mg / mL.
[0100] The present application provides a nucleic acid, which is used to encode a polypeptide of any one of SEQ ID Nos: 1-42.
[0101] The present application provides a composition, which comprises a polypeptide of any one of SEQ ID Nos: 1 to 42. In some embodiments, the composition further comprises a pharmaceutically, food or health product acceptable carrier, auxiliary material and active ingredient.
[0102] In the present application, there is no limitation on the pharmaceutically, food or health product acceptable carriers, excipients and active ingredients, which may be the commonly used carriers, excipients or active ingredients in the art.
[0103] The present application provides the use of the above-mentioned polypeptide or the above-mentioned composition in the preparation of a drug for lowering uric acid or treating hyperuricemia.
[0104] The present application provides a drug for reducing uric acid or treating hyperuricemia, which comprises the above-mentioned polypeptide or the above-mentioned composition.
[0105] Example
[0106] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage. The reagents or instruments used without indicating the manufacturer are all conventional reagent products that can be obtained commercially.
[0107] Example 1: Using the "top-down" method to obtain polypeptides
[0108] Take giant salamander bone powder and add deionized water at a material-liquid ratio of 1:12.5, use 1M sodium hydroxide to adjust the pH to 10.0±0.5, then add 2709 alkaline protease, the concentration of alkaline protease is 0.6% (i.e., the volume ratio of protease to solution), stir in a water bath for enzymolysis, the enzymolysis temperature is 40°C, the enzymolysis pH is 9, the enzymolysis time is 4h, and then the protease is inactivated (100°C, 10min), the enzymolysis solution is cooled to room temperature and centrifuged (5,000×g, 10min) to obtain the supernatant, i.e., giant salamander bone powder enzymolysis extract, add 75% ethanol to the giant salamander bone powder enzymolysis extract for alcohol precipitation, the alcohol precipitation time is 6h, and stand overnight, centrifuge (5,000×g, 20min) to obtain the supernatant, and rotary evaporate at 50°C to obtain giant salamander bone peptide extract (ADBP).
[0109] (1) ADBP quality evaluation
[0110] According to national standards, the nutritional indicators (water content, total protein, ash content), mineral elements (calcium, phosphorus, potassium, sodium, magnesium, iron, zinc, selenium), amino acid composition and heavy metal indicators (mercury, lead, arsenic, cadmium) of giant salamander bone peptide extract were evaluated. The results are shown in Tables 1-4, respectively. The method for determining the nutritional indicators was determined by the method for determining protein in the first method of national standard GB 5009.5-2016.
[0111] The moisture content was determined using the first method of national standard GB 5009.3-2016;
[0112] The crude fat content was determined using the second method of national standard GB 5009.6-2016;
[0113] The ash content was determined using the first method of national standard GB 5009.4-2016;
[0114] The determination method of mineral elements is determined by the method in the first method of national standard GB 5009.268-2016;
[0115] The amino acid composition was determined by the method in national standard GB 5009.124-2016.
[0116] The determination method of heavy metal indicators (mercury, lead, arsenic, cadmium) is:
[0117] The first method of national standard GB 5009.17-2014 was used to determine the total mercury, the second method of national standard GB 5009.12-2017 was used to determine the lead content, the first method of national standard GB 5009.11-2014 was used to determine the total arsenic, and the first method of national standard GB 5009.15-2014 was used to determine the cadmium content.
[0118] Table 1 Basic physical and chemical properties of ADBP
[0119] project percentage(%) Moisture 3.77±1.47 Crude Protein 83.75±1.91 Crude fat 0.90±0.10 Ash 12.57±0.06
[0120] Table 2 Major and trace elements of ADBP
[0121] Macroelements and trace elements Content (mg / kg) P 758.67±130.24 K 7743.33±565.36 Na 5736.67±165.03 Fe 6.52±0.16 Zn 3.51±0.13 Se 0.69±0.05
[0122] Table 3 Heavy metal index of ADBP
[0123] project Content (mg / kg) Hg 0.03±0.01 Pb ND As ND Cd ND
[0124] Note: ND means not detected.
[0125] Table 4 Amino acid composition and content of ADBP
[0126] Amino Acid Type Content (mg / kg) Gly 7.54±0.18 Ala 5.56±0.17 Val 3.50±0.10 Leu 5.66±0.18 Ile 3.37±0.12 Pro 5.50±0.14 Phe 3.11±0.15 Met 1.31±0.01 Tyr 2.45±0.13 Ser 4.14±0.15 Thr 3.41±0.11 Asp 6.94±0.30 Glu 12.00±0.53 Lys 5.57±0.18 Arg 5.64±0.22 His 1.87±0.03
[0127] It can be concluded from Tables 1-4 that the nutritional components of ADBP show that it is rich in crude protein, reaching 83.75±1.91%; ADBP is rich in major elements such as P, K, Na, and Se (0.69±0.05 mg / kg), which is actually within the standard range of selenium-rich food (0.2-2.0 mg / kg); various heavy metal indicators of ADBP are within the national food standard range, and the actual content is very low or below the detection limit; the hydrophobic amino acids in ADBP are 28.01±1.04 mg / kg, accounting for 36.1% of the total amino acids.
[0128] (2) ADBP molecular weight distribution and weight average molecular weight and number average molecular weight
[0129] The method of Yu et al. (YU Y, HU Q, LIU J, et al. Isolation, purification and identification of immunologically active peptides from Hericium erinaceus [J]. Food and Chemical Toxicology, 2021, 151: 112111.) was referenced and modified, and the molecular weight distribution of ADBP was analyzed using an Agilent 1260 high performance liquid chromatograph (equipped with a differential detector). The chromatographic column used was TSK-Gel G2000SWXL (300mm×7.8mm), the mobile phase system was acetonitrile-water (45:55, containing 0.1% trifluoroacetic acid), the detection wavelength was 220nm, the flow rate was 0.5mL / min, the column oven temperature was 30°C, and the injection volume was 10μL. The standards used for the standard curve were cytochrome C (12,384 Da, purchased from Beijing Solebao), aprotinin (6511 Da, purchased from Beijing Solebao), artificial synthetic peptide VPSGPLGPEGPR (SEQ ID NO: 21, 1161.6 Da, purchased from Hefei Guopeptide Biotechnology Co., Ltd.), glutathione (307 Da, purchased from Beijing Solebao), Glutamate (147 Da, purchased from Beijing Solebao), and a standard curve y = -0.3705x + 10.4769 (y = Log MW, R2 = 0.997) was drawn. The molecular weight distribution of the giant salamander bone peptide extract was determined as shown in the following figure. Figure 1 shown.
[0130] from Figure 1 It can be seen that in ADBP, polypeptides with a molecular weight of "less than 1000Da" account for 77.78±1.15%, polypeptides with a molecular weight of "1000-3000Da" account for 21.22±1.15%, polypeptides with a molecular weight of "3000-5000Da" account for 0.81±0.27%, and polypeptides with a molecular weight of "greater than 5000Da" account for 0.17±0.11%.
[0131] The giant salamander bone peptide extract was analyzed by GPC (gel permeation chromatography), and the weight average molecular weight of the giant salamander bone peptide extract was found to be 513±17.04 g / mol, and the number average molecular weight was 454.67±97.35 g / mol.
[0132] 1.3 Acquisition of peptides
[0133] Agilent 1260 Infinity II preparative HPLC was used to perform preliminary separation of the ADBP prepared by the above method. Chromatographic conditions: the chromatographic column was an Agilent 5prep-C18 column (50×21.2mm); mobile phase: pump A was aqueous phase (containing 0.1% TFA), pump B was acetonitrile (containing 0.1% TFA); flow rate: 10mL / min; injection volume: 0.9mL; detection wavelength: 214nm, 280nm; elution conditions were 10% acetonitrile system isocratic elution for 30min. The experiment prepared a 150mg / ml ADBP stock solution (2.97g ADBP) and passed it through a 0.22μm filter membrane, and the ADBP chromatogram was divided into three separation components: ADBP-1 (1.73g), ADBP-2 (0.38g) and ADBP-3 (0.43g) ( Figure 2 A), 60℃ rotary concentration and freeze-drying for use, the total sample recovery rate was 85.52%. The XOD inhibition rate of ADBP separation components was evaluated by chemical method, and the XOD inhibition rate of 20mg / mL ADBP-2 component was 67.82±6.96%, which was significantly higher than ADBP-1 (57.76±11.74%) and ADBP-3 (40.80±6.54%) (p<0.05, Figure 2 B).
[0134] Therefore, ADBP-2 fraction was selected for the second separation.
[0135] Among them, the chemical method operates as follows:
[0136] Take 50 μL of the sample to be tested and 50 μL of XOD (0.05U / mL) and incubate in a 96-well plate at 37°C for 10 minutes, then add 150 μL of 0.1mmoL / L xanthine solution, immediately place in the microplate reader, and record the dynamic changes of the absorbance value of the reaction system at 290nm within 2 minutes (every 20s). The blank control and positive control are replaced by PBS and allopurinol, respectively. The XOD inhibition rate is calculated as follows:
[0137]
[0138] Among them, V0 is the initial reaction rate of the enzymatic reaction system of the control group, and V1 is the initial reaction rate of the enzymatic reaction system of the sample group;
[0139] ADBP-2 was analyzed by Agilent 1260 Infinity II preparative HPLC.
[0140] Separation. Chromatographic conditions: Agilent 5prep-C18 column (50×21.2 mm); flow
[0141] Mobile phase: A pump is water phase (containing 0.1% TFA), B pump is acetonitrile (containing 0.1% TFA); flow rate: 5mL / min; injection volume: 0.9mL; detection wavelength: 214nm, 280nm; elution conditions: 10% acetonitrile system isocratic elution for 25min. Experimental configuration 150mg / ml ADBP-2 stock solution (1.05g) and passed through 0.22μm filter membrane,
[0142] The ADBP chromatogram was divided into three separated components: ADBP-21 (0.27 g), ADBP-22 (0.23 g), and ADBP-23 (0.39 g). Figure 2 C), concentrated by rotation at 60°C and freeze-dried for later use, with an overall recovery rate of 84.76%.
[0143] The XOD inhibition rates of the ADBP-2 fractions were evaluated by chemical methods. The XOD inhibition rates of the 20 mg / mL ADBP-21 and ADBP-22 fractions were 73.91±4.10% and 74.20±4.02%, respectively, which were significantly higher than those of the ADBP-23 fraction (55.07±8.00%, Figure 2 D), wherein the chemical method is the same as above. Therefore, ADBP-22 was selected as the component for subsequent mass spectrometry identification.
[0144] Orbitrap Fusion mass spectrometer was used to analyze the components of ADBP-22. Gradient elution used 0.1% trifluoroacetic acid aqueous solution (A)-0.1% trifluoroacetic acid acetonitrile solution (B) as the mobile phase, with a flow rate of 250
[0145] nL / min. Gradient program: 0-2min, 3-7% B; 2-52min, 7-22% B; 52-62min, 22-35% B; 62-64min, 35-90% B; 64-84min, 90-90% B. m / z scanning range: 300-2000,
[0146] Target 2e 5 ions with a resolution of 120,000. The mass spectrometer was set to perform data-dependent acquisition in the highest speed mode of high-energy collision dissociation. Based on the collected MS / MS spectral data, DeNovoGUI software was used to analyze the
[0147] (Version 1.16.2, Max Planck Institute, Munich, Germany) was used for peptide sequence identification. A total of 329 peptide sequences were identified in this experiment, and 7 peptides were selected based on the abundance and amino acid characteristics of the peptides, as shown in Table 5.
[0148] sequence Abundance m / z[Da] TEAPLNPK (SEQ ID NO: 1) 14164000000 868.46543 HDEPVTIPNKPN (SEQ ID NO: 2) 5971900000 1359.6783 GPRGPQGPS (SEQ ID NO: 3) 5560700000 851.42496 RGPPGPS (SEQ ID NO:4) 5249800000 666.34492 LDFE (SEQ ID NO: 5) 5003700000 522.23258 PAW (SEQ ID NO:6) 1984100000 372.17976 GPAGPSGPR (SEQ ID NO:7) 1262200000 794.4035
[0149] Example 2: Obtaining polypeptides using a "bottom-up" approach
[0150] The experiment used the cartilage of giant salamanders raised in Luoyang, Henan as the research object. The transcriptomic method was first used to obtain the transcriptome information of giant salamander cartilage. A total of 15,183 proteins were annotated through simulated translation, and a giant salamander cartilage protein library was established, which was used as a protein sequence information comparison database required for protein identification during proteomic data processing. The giant salamander cartilage was then subjected to proteomic sequencing, and a total of 6,385 polypeptide sequences were identified. Using the giant salamander cartilage protein database established above as a reference, a total of 1,271 proteins were annotated. The above 1,271 proteins were imported into the existing protein computer-assisted hydrolysis server (PeptideCutter,
[0151] PeptideMass, BIOPEP, etc.) respectively selected trypsin and chymotrypsin
[0152] (Chymotrypsin), trypsin / chymotrypsin (Trypsin / Chymotrypsin), pepsin (Pepsin), proteinase K (Proteinase K) and thermolysin (Thermolysin) were used for single enzyme and compound enzyme simulation enzymolysis, and 21504, 26767, 27049, 30651, 16248, and 26647 giant salamander cartilage polypeptides were obtained in sequence, totaling 148866 (molecular weight 250-3000Da). The inventors of this application have counted 60 identified uric acid-lowering polypeptide sequences in databases such as Web of science and China National Knowledge Infrastructure in the past decade (2013-2023), and used this as a database to perform machine learning processing on the 148866 polypeptides in this experiment, and a total of 3638 polypeptides with a similarity higher than 85% were screened out. The 3D structure of Xanthine Oxidase (XOD) was obtained from the protein database PDB (http: / / www.rcsb.org / ), from which 3NVY, a bovine XOD crystal structure, was retrieved. Using 3NVY as the receptor protein and the 3638 selected peptides as ligands, molecular docking was performed using semi-flexible docking, and 900 peptides were obtained, of which 524 were 2-8 peptides. Studies have shown that hydrophobic peptides can better bind to XOD to inhibit it. The 524 peptides were then sorted by hydrophobicity, and the top 35 peptides were selected as potential active peptide sequences, as shown in Table 6.
[0153] Table 6
[0154]
[0155]
[0156] Note: GRAVY: The larger the positive value, the more hydrophobic it is; the larger the negative value, the more hydrophilic it is.
[0157] Experimental Example 1 In vitro xanthine oxidase inhibition effect of synthetic peptides
[0158] 42 polypeptides (purity>95%) were obtained by artificial synthesis, and the xanthine oxidase inhibition rate was used as the evaluation index. The xanthine oxidase inhibition rate IC was determined by conventional methods in the field. 50 , the results are shown in Table 7.
[0159] Table 7 Artificially synthesized uric acid-lowering giant salamander bone peptide active polypeptide sequence IC 50 value
[0160]
[0161]
[0162] It was found that the above 42 uric acid-lowering peptides all had a good effect of inhibiting xanthine oxidase activity in vitro. 50 The values are between 0.31-3.35 mg / mL.
[0163] After ranking the above 42 peptides, the experiment further selected the top 8 uric acid-lowering peptides (IC 50 The value was less than 1 mg / mL) to conduct an intervention experiment on hyperuricemia mice.
[0164] The experiment used SPF C57BL / 6J male mice, 6-8 weeks old, weighing 21g, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. The animals were raised in an SPF animal laboratory, with a temperature of 20-26℃, a relative humidity of 40-70%, and a 12h:12h day and night lighting. The mice were adaptively fed for 7 days, and the animals had free access to food and water during the experiment. From day 0 to day 7, the control group and the model group were gavaged with 0.25% CMC-Na every day, and the positive group and the test group were gavaged with 10mg / kg allopurinol and 100mg / kg different peptides, respectively. On the 7th day, mice in each group were intraperitoneally injected with 200uL 0.25% CMC-Na for 1 hour after gavage. Mice in the control group were intraperitoneally injected with 200uL modeling agent (0.25% sodium carboxymethyl cellulose suspension containing 300mg / kg potassium oxonate and 200mg / kg hypoxanthine). After another hour, the mice were anesthetized and blood was collected from the heart. Serum (uric acid, creatinine, urea nitrogen) and liver (XOD) indexes were tested according to the steps of the kit of Nanjing Jiancheng Bioengineering Institute. The results are shown in the figure. Figure 3 As shown, Figure 3 A in the figure is a schematic diagram of experimental data. Figure 3 B in the figure is a schematic diagram of xanthine oxidase activity in the liver. Figure 3 The C in the figure is a diagram of blood uric acid level. Figure 3 D in the figure is a diagram of blood creatinine level. Figure 3 E in the figure is a schematic diagram of blood urea nitrogen level.
[0165] Depend on Figure 3 The BC in the model group showed that compared with the control group, the XOD activity and blood uric acid level in the model group were significantly increased (p<0.05), indicating that the hyperuricemia mouse model was successfully established. Compared with the model group, the allopurinol group mice could significantly inhibit the XOD activity to reduce the increase in blood uric acid level (p<0.05, Figure 3 B-3C). Figure 3 As shown in B, compared with the model group, the XOD activity of mice in the YLAFLR, HDEPVTIPNKPN, GPAGPSGPR, GPRGPQGPS, and AVLVFR groups was significantly decreased (p<0.05), while the XOD activity of mice in the RGPPGPS, FTLR, and LDFE groups showed no significant changes (p>0.05).
[0166] Figure 3 The results in C showed that the serum uric acid levels of mice in the HDEPVTIPNKPN and AVLVFR groups were significantly lower than those in the model group (p<0.05), and there were no significant changes in the other groups, but the serum uric acid levels of mice in the YLAFLR, RGPPGPS, FTLR, LDFE, and GPAGPSGPR groups showed a certain downward trend (p>0.05). In addition, the experiment further detected the levels of creatinine and urea nitrogen in serum to evaluate the effects of the eight peptides on kidney function. Figure 3 The DE in the model group showed that the levels of creatinine and urea nitrogen in the model group were significantly higher than those in the control group (p<0.05), indicating that acute hyperuricemia in mice was accompanied by renal damage. There was no significant difference in serum renal damage indicators between the allopurinol group and the model group (p>0.05). Compared with the model group, the serum creatinine of the AVLVFR group decreased significantly ( Figure 3 D in the figure, p<0.05), and the serum creatinine levels of mice in the other polypeptide groups showed a certain downward trend ( Figure 3D in, p>0.05), which has the effect of protecting kidney function. In addition, the serum urea nitrogen level of mice in the FTLR, LDFE, HDEPVTIPNKPN, GPAGPSGPR, GPRGPQGPS, and AVLVFR groups was slightly lower than that in the model group (p>0.05), suggesting that the intervention of these peptides has a potential trend to reduce serum urea nitrogen. The intervention time and concentration of peptides may be an important reason for the peptides to protect kidney function from damage. In summary, HDEPVTIPNKPN and AVLVFR have good effects in inhibiting XOD activity and reducing blood uric acid, and can be used as candidate peptides for subsequent research on the mechanism of uric acid lowering. In addition, the other 6 peptides also have certain XOD activity inhibition effects, uric acid lowering effects and kidney protection effects.
[0167] The above is only the preferred embodiment of the present application, and does not limit the present application in other forms. Any technician familiar with the profession may use the above disclosed technical content to change or modify it into an equivalent embodiment with equivalent changes. However, any simple modification, equivalent change and modification made to the above embodiment based on the technical essence of the present application without departing from the technical solution of the present application still falls within the protection scope of the technical solution of the present application.
Claims
1. A polypeptide, wherein the polypeptide is selected from any one of SEQ ID Nos: 1-42. A nucleic acid encoding the polypeptide according to claim 1.
3. A composition comprising the polypeptide of claim 1.
4. The composition according to claim 3, wherein It also contains pharmaceutically, food or health product acceptable carriers, auxiliary materials and active ingredients.
5. Use of the polypeptide according to claim 1 or the composition according to claim 3 or 4 in the preparation of a medicament for lowering uric acid or treating hyperuricemia.
6. A drug for reducing uric acid or treating hyperuricemia, comprising the polypeptide according to claim 1 or the composition according to claim 3 or 4.
Citation Information
Patent Citations
Sipunculus nudus oligopeptide capable of promoting bone development and preparation method and application thereof
CN112679580A
Giant salamander bone meal extract as well as preparation method and application thereof
CN114073754A
Composition capable of reducing uric acid and application
CN115715796A
A saury maillard peptide having uric acid-decreasing activity and its preparation method and application
US20180042264A1
